Abstract
The synthesis of racemic 2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl} phenyl)propionic acid (VUFB 20615) and preparation of 2-methyl-2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl)propionic acid (VUFB 20623) as new potential antileukotrienic drugs are described. Due to a low reactivity of the 4-substituted aryl bromides (coupling of the 4-substituted aryl bromides do not provide an activating functional group with 4- methoxybenzene-1-thiol), special conditions, in particular specific heterogeneous copper catalysts, were used. Various methods of 2-substituted propionic acid preparation have been discussed in the paper. In vitro cytotoxicity testing was performed using a microplate colorimetric acid phosphatase assay. Antiplatelet activity was evaluated using in vitro test in human platelet-rich plasma.
Keywords: antileukotrienic drugs, aryl bromides, copper catalysts, microplate colorimetric acid phosphatase
Current Organic Chemistry
Title: Preparation of 2-(4-{[4-(Quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) Propionic Acid (VUFB 20615) and 2-Methyl-2-(4-{[4-(quinolin-2- ylmethoxy)Phenyl]sulfanyl}phenyl)Propionic Acid (VUFB 20623) as Potential Antileukotrienic Agents
Volume: 8 Issue: 13
Author(s): Josef Jampilek, Martin Dolezal, Jiri Kunes, Petra Víchova, Ivan Raich, Daniel Jun, Robert O'Connor and Martin Clynes
Affiliation:
Keywords: antileukotrienic drugs, aryl bromides, copper catalysts, microplate colorimetric acid phosphatase
Abstract: The synthesis of racemic 2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl} phenyl)propionic acid (VUFB 20615) and preparation of 2-methyl-2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl)propionic acid (VUFB 20623) as new potential antileukotrienic drugs are described. Due to a low reactivity of the 4-substituted aryl bromides (coupling of the 4-substituted aryl bromides do not provide an activating functional group with 4- methoxybenzene-1-thiol), special conditions, in particular specific heterogeneous copper catalysts, were used. Various methods of 2-substituted propionic acid preparation have been discussed in the paper. In vitro cytotoxicity testing was performed using a microplate colorimetric acid phosphatase assay. Antiplatelet activity was evaluated using in vitro test in human platelet-rich plasma.
Export Options
About this article
Cite this article as:
Jampilek Josef, Dolezal Martin, Kunes Jiri, Víchova Petra, Raich Ivan, Jun Daniel, O'Connor Robert and Clynes Martin, Preparation of 2-(4-{[4-(Quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) Propionic Acid (VUFB 20615) and 2-Methyl-2-(4-{[4-(quinolin-2- ylmethoxy)Phenyl]sulfanyl}phenyl)Propionic Acid (VUFB 20623) as Potential Antileukotrienic Agents, Current Organic Chemistry 2004; 8 (13) . https://dx.doi.org/10.2174/1385272043370041
DOI https://dx.doi.org/10.2174/1385272043370041 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Aberrant DNA Methylation and Prostate Cancer
Current Genomics High Mobility Group Box 1 Protein as a Potential Drug Target for Infection- and Injury-Elicited Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Interactions of Polyphenols with Plasma Proteins: Insights from Analytical Techniques
Current Drug Metabolism Development of Novel Therapeutic Strategies for Lung Cancer: Targeting the Cholinergic System
Current Medicinal Chemistry Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Earthworms as a Source of Bioactive Molecules
Current Bioactive Compounds Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Spectral Imaging Technology - A Review on Skin and Endoscopy Applications
Recent Patents on Medical Imaging Discovery of 4-Aryl-4H-Chromenes as Potent Apoptosis Inducers Using a Cell- and Caspase-Based Anti-Cancer Screening Apoptosis Program (ASAP): SAR Studies and the Identification of Novel Vascular Disrupting Agents
Anti-Cancer Agents in Medicinal Chemistry Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents